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In randomized controlled trials, ordinal outcomes are commonly used as primary
endpoints to measure the efficacy of interventions. Conventionally, the ordinal out-
come has been analyzed on the original scale, by first creating a binary measure or by
treating the outcome as a continuous variable. It has been suggested that analyzing
the data on the original ordinal scale provides the most powerful test for detecting
a treatment effect. However, there are situations when dichotomizing the ordinal
outcome yields higher power.
In this thesis, we review the conventionally used statistical methods for analyz-
ing ordinal outcomes, and apply these methods to simulated hypothetical trials. The
simulated hypothetical trials are defined based on different distributional assump-
tions for the control arm. To test for a treatment effect, we apply the cumulative logit
model to the ordinal outcome and the Fisher’s exact test to the dichotomized out-
come. The power to detect a treatment effect is compared across these two methods
for each control arm distribution and a variety of treatment effect sizes.
The power to detect the treatment effect depends on the control arm distribu-
tion and the anticipated treatment effect. We found that dichotomizing the ordinal
outcome can yield higher power to detect a treatment effect if the difference in the
proportion of patients at a single level of the ordinal outcome is large and the re-
maining differences are spread over the remaining categories as opposed to shifted
into a single category.
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Ordinal outcomes are commonly used as primary endpoints in randomized con-
trolled trials; however, defining the treatment effect when the primary endpoint is an
ordinal outcome is challenging. Defining the treatment effect requires careful consid-
erations; including the interpretation of the ordered categories, the clinical relevance
of each ordered category, the distribution of the outcome within the control arm and
the anticipated effect of the treatment on the outcome.
It is common to apply a fixed dichotomy to an ordinal outcome to provide a
simplified definition of the treatment effect. However, several recent papers have
suggested that preserving the characteristics of the ordinal outcome (natural ordering
and number of ordered levels) in the definition of and statistical analysis estimating
the treatment effect provides higher power relative to the fixed dichotomy [1, 2].
To address this conflict, in this thesis, we review the conventionally used treat-
ment effect definitions and subsequent statistical methods when analyzing an ordinal
outcome in a randomized clinical trial. We apply these methods to data from two
completed Phase II trials on stroke patients, the MISTIE II trial and the CLEAR II
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trial. Using the MISTIE II and CLEAR II trial data, we simulate hypothetical trials
and demonstrate the power to detect the treatment effect of an ordinal outcome vs.
fixed dichotomy. We conclude by providing guidance for researchers to optimally
design and analyze a randomized clinical trial with an ordinal outcome.
1.1 Definitions and notation
Throughout this thesis, we consider a 1:1 randomized controlled trial, such that
n subjects are randomly assigned to receive treatment A ∈ {0, 1}, where A ∼
Bernoulli(0.5). The outcome Y ∈ {1, · · · , K} represents an ordered categorical
outcome with K possible values. Define pk = Pr(Y = k) for k = 1, · · · , K, with∑K
k=1 pk = 1. The data consists of (Ai, Yi) for each subject i in i = 1, · · · , n, and we
define p0k and p1k as Pr(Yi = k | Ai = 0) and Pr(Yi = k | Ai = 1), respectively. The
outcome Y with K ordinal levels and the treatment assignment can be displayed in a
2 x K contingency table (Table 1.1) with n0k and n1k denoting the number of treated
and control patients in the Yi = k category, respectively. We additionally define n.k
as the number of patients in the Y = k outcome category regardless of treatment
assignment, i.e. n.k = n0k + n1k. And let n0. =
∑K
k=1 n0k and n1. =
∑K
k=1 n1k be the
number of patients in the control group (A = 0) and in the treated group (A = 1),
respectively.
Table 1.1: 2 x K contingency table
Y = 1 Y = 2 · · · Y = K
A = 0 n01 n02 · · · n0K n0.
A = 1 n11 n12 · · · n1K n1.
n.1 n.2 · · · n.K n
2
Chapter 2
Review of statistical methods
Researchers have historically defined the treatment effect and appropriate statis-
tical analysis for an ordinal outcome using one of three approaches: 1) maintain the
outcome on the original scale, 2) dichotomize the ordinal outcome to create a binary
outcome, and 3) treat the ordinal outcome as a continuous variable. In each of the
three cases, the treatment effect has a different definition and the corresponding sta-
tistical methods to estimate and test the treatment effect vary. In this section, we
will review each approach providing the definition of the treatment effect and describ-
ing the statistical procedure to estimate and/or test the treatment effect. Table 2.1
summarizes the three approaches by providing a description of summary statistics,
null and alternative hypotheses and corresponding statistical methods.
2.1 Ordinal analysis
In the ordinal anlaysis, the outcome variable is treated as the original ordered
categorical variable. There are several commonly used statistical methods to define
and test for a treatment effect of the ordered outcomes. Some of which utilizes
3
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the ranks of the outcomes to test a treatment effect, such as the Mann-Whitney
U/Wilcoxon test and robust ranks test. And some takes a parametric approach,
such as the cumulative logit model. The goal of each statistical method is to test the
null hypothesis that the distribution of the ordinal outcome is the same in the control
and treatment group, i.e. p0k = p1k for all k in 1, · · · , K, vs p0k 6= p1k for at least one
k. The specific ways of stating the null and alternative hypothesis and the statistical
approaches for comparing the distributions across the control and treatment groups
vary.
2.1.1 Mann-Whitney U/Wilcoxon test
The Mann-Whitney U/Wilcoxon test is used to test the null hypothesis that
the outcomes in each treatment group are sampled from the same distribution. To
test if the observed samples from the two treatment groups share the same distribu-
tion, Mann-Whitney U/Wilcoxon test states its null hypothesis as Pr(Y0j > Y1m) =
Pr(Y0j < Y1m) = 12 , where Y0j and Y1m are randomly selected observations from the
4
control and treatment group, respectively. The alternative two-sided hypothesis is
Pr(Y0j > Y1m) 6= Pr(Y0j < Y1m) 6= 12 [3].
The Mann-Whitney U/Wilcoxon test ranks all of the observations from lowest
to highest, regardless of the treatment assignment. Then the sums of ranks for each
treatment group is computed as S0 =
∑n
i=1(1 − Ai)Ri and S1 =
∑n
i=1 AiRi for the
control and treatment group, respectively, where Ri represents the rank of outcome
Yi without differentiating the treatment assignment [4]. Then, the U statistic [5] is
the difference in the rank sums between the treatment groups, which can take either
value of the U0 and U1 defined below.
U0 = n0.n1. +
n0.(n0. + 1)
2 − S0
U1 = n0.n1. +
n1.(n1. + 1)
2 − S1
If the U statistic is larger than its critical value, there is statistical evidence to
support differences in the distributions of Y between the treatment groups.
In the case of larger sample sizes (typically >10 in each group), we can use a
normal approximation for the distribution of U such that
U ∼ Normal(n0.n1.2 ,
n0.n1.(n+ 1)
12 )





, and conduct the significance
test.
When there are many tied ranks present,such as the case with an ordinal outcome,
more complicated corrections are required in order to use the normal approximation.
The tied observations are assigned with the average of the ranks when no ties were
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assumed. If the ties occur within the same treatment arm, we do not need to make a
correction because the rank sums (S0 and S1) are not affected by the ties. However
when the ties occur across both treatment groups, it affects the variability of each











where g is the number of sets of tied ranks, and tm is the number of tied ranks in
the m th set of tied ranks[3].
2.1.2 Robust ranks test
The robust ranks test loosens the null hypothesis of Mann-Whitney U/Wilcoxon
test, and compares the medians of the ordinal outcomes between the two treatment
group, without assuming the distributional equivalence between the two groups. The
null hypothesis of the robust ranks test states that θ0 = θ1, where the θ0 and θ1
represent the medians of the distributions of the populations for the control and
treatment groups, respectively. Correspondingly, the alternative hypothesis of a two-
tailed test is stated as θ0 6= θ1. In the robust ranks test, we order Yi from smallest
to largest value, regardless of treatment assignment, and define Ri as we did for the
Mann-Whitney U/Wilcoxon Test. With Ri, we define Tj as the j th observation in
the treated group, and Cl as the the l th observation in the control group.
Then for each Tj, let W (CTj) be the number of observations in the control group










We define the variances for W (CTj) and W (TCl) as VT =
∑n1.




l=1[W (TCl −W (TC)]2, respectively [3]. We define the test statistic of the
robust ranks test, Ẁ , as:
Ẁ = n1.W (CT )− n0.W (TC)
2
√
VT + VC +W (CT )W (TC)
If the p-value of the Ẁ statistic is smaller than its critical value, the null hypoth-
esis is rejected, thus supporting the alternative hypothesis of different medians in
the distribution of outcomes in the treatment groups. When the sample sizes are
sufficiently large, the distribution of Ŵ is approximated by the standard normal dis-
tribution, thus we can use Ŵ as an approximate of the z statistic. Similar to the
Mann-Whitney U/Wilcoxon test, many ties in the ranks can occur when we have
ordered categorical outcomes. In such cases, adjustments are made to account for
the ties by redefining W (CTj) (W (TCl)) as the sum of the number of observations
in the control (treated) arm that are less than Tj (Cl) and the half the number of
observations in the control (treated) arm that are equal to Tj (Cl).
2.1.3 Cumulative logit model
Unlike the Mann-Whitney U test and the robust rank test, the cumulative logit
model defines a parametric model describing differences in the distribution of the
ordinal outcome across the treatment groups. When there are K ordered categories
for the outcome Y , K − 1 cumulative logits are defined, each comparing the odds of
the response being less than or equal to k across the two treatment groups:
logit [Pr(Y ≤ k | A)] = log
[
Pr(Y ≤ k | A)
Pr(Y > k | A)
]
= αk + βk × A, for k = 1, ...K − 1
7
αk represents the log odds of Y being less than or equal to k in the control group
(A = 0), and βk represents the difference in the log odds of Y being less than or
equal to k comparing the treatment (A = 1) and control (A = 0) groups.
The cumulative logit model provides a 1-to-1 mapping from the cumulative logits











In this model, the null hypothesis of no treatment effect reduces to testing if
βk = 0 for all k = 1, ..., K − 1. The alternative hypothesis is βk 6= 0 for at least one
k = 1, ..., K − 1. To test the null hypothesis, a K − 1 degree of freedom likelihood
ratio test is conducted.
One draw back to this approach is that the treatment effect is defined by K − 1
values of βk and thus is not represented by a single parameter within the regression
model. A special case of the cumulative logit model is the proportional odds model,




Pr(Y ≤ k | A)
1− Pr(Y ≤ k | A)
]
= αk + β × A, for k = 1, ...K − 1
β is the difference in the log odds of Y being less than or equal to k comparing
the treatment and control groups. The proportional odds assumption can be often
violated in real data. Although there are statistical tests to perform to assess the
validity of the proportional odds assumption, such as Brant test [6] and likelihood
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ratio test with the cumulative logit model, these tests tend to be underpowered to
reject the assumption of proportional odds. In cases where the cumulative logit
model is the true model and the proportion odds model is fit, β may or may not
be an appropriate summary of the treatment effect within a randomized trial, even
when the results of the proportional odds assumption test tells that the assumption
is valid.
2.2 Dichotomous analysis
Oridnal outcomes can be dichotomized at a specific threshold to create a binary
outcome (i.e. "good" vs. "bad" outcome). We define the dichotomized outcome as
Y ∗i = I(Yi ≤ c) for some cut-off c = 1, ..., K − 1, and p0c = Pr(Y ∗i = 1|Ai = 0)
and p1c = Pr(Y ∗i = 1|Ai = 1) for the control and treatment groups, respectively.
The null hypothesis for the fixed dichotomy approach is p0c = p1c, and the two-sided
alternative hypothesis is p0c 6= p1c. Several statistical methods can be used to analyze
binary outcomes, including logistic regression, the χ2 test, and Fisher’s exact test.
In the following section, we provide details of the Fisher’s exact test.
Table 2.2: 2 x 2 contingency table
Y ≤ c Y > c
A = 0 n0c n0. − n0c n0.
A = 1 n1c n1. − n1c n1.
n.c n− n.c n
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2.2.1 Fisher’s exact test
When the sample size is small or one of the expected values in a 2 x 2 contingency
table is less than 1, the Fisher’s exact test can be used to test the independence
between a binary outcome and the treatment assignment, see Table 2.2. To reject
the null hypothesis that p0c = p1c, the observed counts in Table 2.2 must be rare if
the data was actually generated under a model where the outcome and treatment
are independent. The p-value for the Fisher’s exact test is obtained by the following




n!n0c!(n0. − n0c)!n1c!(n1. − n1c)!
Then, calculate all the other probabilities from the possible 2 x 2 contingency ta-
bles with the same marginal frequencies (n.c, n − n.c, n0., n1.) as the observed 2 x 2
contingency table. Finally, the two-sided p-value is obtained by adding up all the
probabilities that are less that or equal to pobs [7].
2.3 Continuous analysis
The K ordered categories can be treated as a numeric or continuous variable, and
subsequently, statistical methods for comparing two independent population means
can be applied such as the two-sample t-test. The null hypothesis of µ0 = µ1 vs.
the alternative that µ0 6= µ1 is tested in the two-sample t-test, where µ0 and µ1 are
the population means of the K ordered categories which take the numeric values
1 through K. The two-sample t-test assumes that the sample means from the two
10
treatment groups are normally distributed; this assumption should be valid in studies
of relatively large sizes e.g. in phase III trials. The test statistic is computed as:







The test statistic t follows a t distribution with n− 2 degrees of freedom [1]. If the
p-value is less than the significance level, we reject the null hypothesis of equal means




The methods discussed in the previous section will be applied to two completed
phase II randomized clinical trials, MISTIE II and CLEAR II. The focus will be on
the hypothesis test of no treatment effect within each trial using the cumulative logit
model and the special case where proportional odds are assumed. In addition, we
apply a fixed dichotomy approach to each trial using the cut-point defined according
to the trials’ protocol and test for a treatment effect using Fisher’s exact test.
3.1 MISTIE II
Minimally invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation,
the MISTIE II trial is a phase-II randomized clinical trial, completed in 2005 with 96
participants with intracerebral hemorrhage (ICH) recruited from the U.S., Canada,
Germany, and U.K. [8]. The primary purpose of the study was to determine the
safety and the efficacy of using a combination of minimally invasive surgery (MIS)
and clot lysis with recombinant tissue plasminogen activator (rt-PA) to remove ICH.
Among the 96 participants, 54 subjects were randomized to receive the combination
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of MIS and rt-PA, and 42 subjects were randomized to receive the standard of care
medical management as per American Heart Association (AHA) guidelines. Two
and four patients from the treatment arm and the control arm were lost to follow-up
within the 180-day of the randomization, leaving 52 and 38 treatment and control
patients, respectively.
The primary safety outcomes included the 30-day mortality, 7-day procedure-
related mortality, 30-day rate of cerebritis, meningitis, bacterial ventriculitis, and 72-
hour rate of symptomatic rebleeding. The primary and secondary efficacy outcomes
were defined based on the modified Rankin Scale (mRS). The mRS consists of 7
ordered categories (0 to 6) representing the degree of disability of the stroke patient
with smaller values indicating less disability: 0 being no symptoms, 1 being no
significant disability despite symptoms, 2 being slight disability, 3 being moderate
disability, 4 being moderately severe disability, 5 being severe disability, and 6 being
dead [9]. The primary efficacy outcome was a binary indicator for the 180-day mRS
being at most 3 and the secondary efficacy outcome was the ordinal mRS at 180-days.
Figure 3.1 (a) displays the cumulative distribution function for the 180-day mRS
for the MISTIE II trial data among 90 patients who completed the 180-day follow-up.
For the primary efficacy endpoint based on the fixed dichotomy with cut-point 3 for
the 180-day mRS, the estimated proportion of patients with a successful outcome
at 180 days is 0.35 (18/52) and 0.24 (9/38) for the treatment vs. control groups,
respectively. There was not a statistically significant difference in the proportion
of patients with a successful outcome at 180-days in this phase II trial (p = 0.18,
Table 3.1) based on the Fisher’s exact test. The secondary efficacy analysis compared
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the distribution of the 180-day mRS across the two treatment groups. We fit both the
cumulative logit model and the proportion odds models to the MISTIE II data, while
considering the mRS ∈ {0, 1, 2} as a single category due to no or small observations
in the lower categories, and in both analyses we found no statistically significant
treatment effect (p = 0.84 for the cumulative logit model and p = 0.4765 for the
proportional odds model). From the cumulative logit model, the estimated log odds
of better than "slight disability" (mRS ≤ 2) comparing the treatment and control
groups is 0.28 (95% Confidence Interval (CI): -1.03, 1.59), the estimated relative log
odds of better than "moderate disability" (mRS ≤ 3) is 0.53 (95% CI: -0.41, 1.48), the
estimated relative log odds of better than "moderately severe disability" (mRS ≤ 4)
is 0.18 (95% CI: -0.67, 1.02), and the estimated relative log odds of better than "severe
disability" (mRS ≤ 5) is 0.10 (95% CI: -0.83, 1.03). Assuming proportional odds
across the K − 1 (K = 5) levels of the ordinal outcomes, the estimated relative log
odds of less disability is 0.27 comparing the treatment and control groups (95% CI:
-0.48, 1.02). The proportional odds assumption is assessed based on the likelihood
ratio test between the cumulative logit model and proportional odds model, and did
not have enough evidence to reject the proportional odds assumption (p = 0.82).
3.2 CLEAR II
Clinical Trial on Treatment of Intraventricular Hemorrhage, the CLEAR II trial
is a phase-II trial completed in 2008 [10]. The purpose of this trial was to determine
the safety of and the lowest efficacious dose and dose frequency of rt-PA injected
via intraventricular catheter (IVC) for the treatment of patients with small ICH
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(ICH≤30) and large intraventricular hemorrhage (IVH) who already have an IVC
placed. There were 3 stages in the CLEAR II trial: CLEAR Safety study, CLEAR
A (dose finding trial), and CLEAR B (dose escalation trial). A total of 100 patients
were enrolled throughout the 3 stages of the trial, recruited from the U.S., Canada,
Germany, and U.K., and of 100 participants, 78 patients were allocated to receive
different doses and dose frequencies of the rt-PA treatment, and 22 patients were
randomized to receive placebo of normal saline during the stage of CLEAR safety
study, in which both the intervention and placebo drug was injected via the IVC.
The primary outcomes were three safety outcomes within the 30-day follow-
up: mortality, incidence of bacterial ventriculitis, and rate of symptomatic bleeding
events. In our reanalysis of this phase II study, we will focus on a efficacy outcome,
the 30-day mRS. The cumulative distribution function for the CLEAR II trial data
is presented in Figure 3.1 (b) based on the 30-day mRS from the 99 patients in total
(22 in the control arm and 77 in the treated arm due to 1 person lost to follow-up).
When the fixed dichotomy approach was used with a cut-point of 4 for the 30-day
mRS, the estimated proportion of patients with a successful outcome (Y ≤ 4) at
30-days is 0.48 (37/77) and 0.27 (6/22) for the treatment and control groups, re-
spectively. There was no statistically significant treatment effect in this phase II
trial (p = 0.09, Table 3.1) based on the Fisher’s exact test. When the distributions
of the 30-day mRS were compared across the two treatment groups, treating the
mRS as the original ordinal scale, with combining the mRS ∈ {0, 1} into a single
category due to no observation in mRS of 0 among the control patients, there was
no evidence of a treatment effect (p = 0.25 based on the cumulative logit model and
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p = 0.24 based on the proportional odds model). From the cumulative logit model,
the estimated log odds of better than "no significant disability despite symptoms"
(mRS ≤ 1) comparing the treatment and control groups is 0.74 (95% CI: -1.41,
2.89), the estimated log odds ratio of better than "slight disability" (mRS ≤ 2) is
0.16 (95% CI: -1.21, 1.52), the estimated relative log odds of better than "moderate
disability" (mRS ≤ 3) is 0.04 (95% CI: -1.09, 1.16), the estimated relative log odds of
better than "moderately severe disability" (mRS ≤ 4) is 0.90 (95% CI: -0.14, 1.94),
and the estimated relative log odds of better than "severe disability" (mRS ≤ 5) is
0.28 (95% CI: -0.87, 1.43). When proportional odds across the K − 1 (K = 6) levels
of the ordinal outcomes are assumed, the estimated relative odds of less disability
is 0.52 (95% CI: -0.35, 1.38). Also, the assumption of proportional odds is assessed
using likelihood ratio test with the cumulative logit model, and did not show enough
evidence to reject the proportional odds assumption (p = 0.27).
Table 3.1: The results of significant test (p-values) based on the MISTIE II and
CLEAR II trial data using different statistical methods
Methods MISTIE II CLEAR II
Fisher’s Exact Test 0.1772 0.0940
Cumulative Logit Model 0.8397 0.2516
Proportional Odds Model 0.4765 0.2388
16
Figure 3.1: Cumulative distributions of mRS by the treatment arms for the MISTIE












































We performed a simulation study to understand the characteristics of the distri-
butions of the ordinal outcome in the treatment and control group such that the use
of the cumulative logit model, the proportional odds model or the fixed dichotomy
are optimal in the sense of achieving high statistical power to detect a treatment
effect. Specifically, we sought to identify characteristics of the distributions of the
ordinal outcome where the fixed dichotomy yields higher power than the cumulative
logit model, and vice versa. In addition, when it is reasonable to assume proportional
odds, is there a benefit in terms of power to detect a treatment effect to chosing the
fixed dichotomy relative to the proportional odds model.
The data for the simulation was generated as follows: n = 500 subjects were
allocated 1:1 to receive treatment or control (250 each per treatment group), the
outcome for subject is a value from a K level ordinal outcome Y , according to the




Pr(Y ≤ k | A)
Pr(Y > k | A)
]
= αk + βk × A, for k = i, ...K − 1
Note that this model reduces to the proportional odds model when βk are the
same for all k.
Our simulation study mimics features of the MISTIE II and CLEAR II trial in




1 if mRS ∈ {0, 1, 2}
2 if mRS ∈ {3, 4}
3 if mRS ∈ {5, 6}
Then α1 represents the log odds of Y = 1 among patients in the control group,
and α2 represents the log odds of Y ≤ 2 among patients in the control group. β1 is
the log odds ratio of Y = 1 comparing the treatment and control groups, and β2 is
the the log odds ratio of Y ≤ 2 comparing the treatment and control groups.
For our simulation study, three different distributions for the ordinal outcome Y
within the control group are considered: the uniform distribution, and the control
distributions observed in the MISTIE II and CLEAR II trials. The graphical display
of theses three control group distributions is presented in Figure 4.1.
We generated the data from the cumulative logit model. The {αk} were uniquely
defined for each control group distribution, such that for the uniform control group
distribution, (α1 = −0.69, α2 = 0.69),(α1 = −2.14, α2 = 0.21) for the MISTIE II
control group distribution, and (α1 = −1.84, α2 = −0.97) for the CLEAR II control
group distribution. We allowed the effect of treatment on the ordinal outcome to be
in a wide range, β1 and β2 each ranging from -0.80 to 0.80.
19




























































(c) CLEAR II Control CDF
For each control group distribution (i.e. (α1, α2)) and (β1, β2) pair, we generated
10,000 simulated studies with the sample size of 250 subjects per group. Within
each simulated study, we computed the following: i) the test of treatment effect
based on the cumulative logit model and ii) the test of treatment effect assuming
a proportional odds model. The power to detect a treatment effect was computed
by taking the proportion of tests that rejected the null hypothesis across the 10,000
simulated studies. In addition, we used exact binomial calculations to compute the
power of the fixed dichotomy based on cut-points Y = 1 and Y = 2. We display the
power to detect a treatment effect within the cumulative logit model, the proportional
odds model and the fixed dichotomy as a function of two odds ratios (eβ1 and eβ2)
using a heat map for each assumed control arm distribution.
For the uniform and CLEAR II control group distributions, a true discrete prob-
ability distribution could not be defined for the treatment group when β1 is small




4.2.1 Cumulative logit model
Figure 4.2 displays the power to detect a treatment effect based on the cumulative
logit model as a function of OR1 and OR2 (OR1 = eβ1 and OR2 = eβ2), each ranging
from 0.45 to 2.23, for each control arm distribution. The x and y axis are centered
at 1, reflecting no treatment effect. The red vertical line at OR1 = 1 represents
the case where there is no difference in the odds of Y = 1 comparing the treatment
groups, and the red horizontal line at OR2 = 1 represents the case where there is
no difference in the odds of Y ≤ 2 comparing the two treatment groups. The 45
degree line represents the case where the proportional odds assumption holds (i.e.
OR1 = OR2). Regardless of the control group distribution, the power to detect
a treatment effect relies on both OR1 and OR2. When OR1 and OR2 are both
1, the cumulative logit model achieves the nominal 5% type I error rate, with the
estimated power of 0.05, 0.06, 0.05 for the uniform, MISTIE II, and CLEAR II
control distributions, respectively. In general, when fixing OR1 (OR2), the power to
detect a significant treatment effect increases as |OR2| (|OR1|) becomes large. Since
the cumulative logit model simultaneously considers the effect of treatment at both
Y = 1 and Y = 2, if at least one of OR1 and OR2 is far from 1, this model can detect
a treatment effect, and thus results in high power. In fact, the estimates of the power
are higher when OR1 and OR2 are not in the same direction with the center at 1
(e.g. OR1(OR2) < 1 and OR2(OR1) > 1), that is to say that the cumulative logit
model can be best utilized when either one of the OR1 and OR2 is far away from 1,
and the difference between OR1 and OR2 is large.
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We observe different patterns in the power to detect a treatment effect when we
change the control arm distribution. Regardless of the control arm distribution, the
power is low to detect a treatment effect when OR1 and OR2 are both close to 1.
For both the uniform and CLEAR II control arm distributions, we see that power
increases more quickly as |OR1| (|OR2|) increases and |OR2| (|OR1|) decreases. For
the MISTIE II trial, the power increases at a slower rate as |OR1| (|OR2|) increases
and |OR2| (|OR1|) decreases. These features are attributable to the control arm
distribution, and the size of the individual OR1 and OR2. We go into further details
in Section 4.2.4.
4.2.2 Fixed dichotomy
Fixed dichotomy at Y = 1
When the outcomes are dichotomized to differentiate between Y = 1 vs. Y > 1,
the power of Fisher’s exact test is solely a function of OR1 (Figure 4.3). This makes
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sense considering OR1 compares the odds of Y = 1 and Y > 1 across the treatment
groups and with a fixed dichotomy defined at Y = 1, OR1 contains all the infor-
mation to define the treatment effect, and as OR1 moves away from 1, the power
increases. At OR1 = 1, the Fisher’s exact test achieves the nominal 5% signifi-
cance level, returning a power of 0.04, 0.04, 0.04 for the uniform, MISTIE II, and
CLEAR II control distribution, respectively. When the assumed control distribution
is MISTIE II or CLEAR II, the power to detect a treatment effect does not increase
as quickly with an increase in |OR1| as it does when we assume the uniform con-
trol distribution. In the MISTIE II and CLEAR II trials, a smaller proportion of
control patients have Y = 1 and for the same OR1, the absolute difference in propor-
tions of patients with Y = 1 comparing the treatment to control arm is smaller for
these two trials compared to the uniform control distribution, hence the lower power.
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Fixed dichotomy at Y = 2




















































Similar intuition applies to the case when the outcomes are dichotomized at
Y = 2, where power is determined only by the value of OR2. For the fixed dichotomy
at Y = 2, we ignore differences in the proportion of patients with Y = 1 in each
treatment group, treatment comparisons are based only on the proportion of patients
with Y ≤ 2 in both treatment groups. In this case, when OR2 = 1, the Fisher’s
exact test achieves the nominal 5% significance level, with the estimated power to
be 0.04, 0.04, 0.04 for the uniform, MISTIE II, and CLEAR II control distribution,
respectively. As expected, Figure 4.4 shows that the power to detect a treatment
effect based on the fixed dichotomy defined by Y = 2 increases as OR2 moves away
from 1. When the uniform control distribution is assumed, the proportion of control
patients in Y ≤ 2 category is 67%, and this contributes to faster increases in power as
OR2 becomes smaller than 1 compared to when OR2 becomes larger than 1. When
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the MISTIE II control distribution is assumed, the power increase is almost identical
regardless of direction of the treatment effect. This happens because the proportion
of control patients in Y ≤ 2 category is 55% in the MISTIE II trial. Whereas in
the CLEAR II control distribution, the proportion of patients in Y ≤ 2 category is
still relatively small (27%), thus the power increase happens quicker as OR2 becomes
larger than 1.
4.2.3 Comparison between cumulative logit model and fixed
dichotomy
























































We compared the power of the test for treatment effect based on the cumulative
logit model and the Fisher’s exact test when the ordinal outcome is dichotomized
at Y = 1 (Figure 4.5) and at Y = 2 (Figure 4.6). We subtracted the power to
detect a treatment effect based on the Fisher’s exact test from the power based on
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the cumulative logit model, thus the red areas of the heat maps represent the cases
where the Fisher’s exact test outperforms the cumulative logit model in terms of
power to detect a treatment effect. We note that overall, the cumulative logit model
is not uniformly better than the fixed dichotomy at Y = 1.
Recall that the power to detect a treatment effect based on the fixed dichotomy
at Y = 1 depends only on OR1. In cases where OR1 is close to 1 but OR2 is
further away from 1, then the cumulative logit model yields higher power to detect
a treatment effect. In general, dichotomizing the ordinal outcome at Y = 1 provides
a test for the treatment effect that has greater power than the test based on the
cumulative logit model when 1 > OR2 > OR1 and 1 < OR2 < OR1.
























































We also compared the power of the test for treatment effect based on the cumula-
tive logit model and the Fisher’s exact test when the ordinal outcome is dichotomized
at Y = 2. For the fixed dichotomy at Y = 2, the power is a function of only OR2 and
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we see that when OR2 is close to 1 but OR1 is away from 1, there is an advantage to
using the cumulative logit model. In addition, the fixed dichotomy generally yields
larger power to detect a treatment effect compared to the cumulative logit model
when 1 < OR1 < OR2 and 1 > OR1 > OR2.
4.2.4 Discussion of specific cases
In the prior sections, we demonstrated that the cumulative logit model (CLM)
does not always provide higher power to detect treatment effects compared to the
fixed dichotomy (FD) approaches. To further explore this finding, we have selected a
few combinations of OR1 and OR2 values to demonstrate when and why the cumula-
tive logit model or fixed dichotomy approaches are preferrable. For each selected set
of OR1 and OR2, Table 4.1 displays the cumulative proportions of patients in each
treatment arm as well as the estimated power based on the cumulative logit model
and fixed dichotomies at Y = 1 and Y = 2 for each control arm distribution.
First, we considered two cases where the cumulative logit model had greater power
to detect a treatment effect compared to the fixed dichotomy. When OR1 = 1.65
and OR2 = 1, the cumulative logit model has higher power to detect a treatment
effect compared to the fixed dichotomy at Y = 1 when the control arm distribution
is uniform or based on the CLEAR II trial. For the MISTIE II trial, the power
is roughly the same for both the cumulative logit model and fixed dichotomy at
Y = 1. In this case, there is no difference in the proportions of patients with
Y ≤ 2 between the treatment arms so that the differences in power are driven
by the proportion of patients with Y = 1. The power of Fisher’s exact test with
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the dichotomy assigned at Y = 1 increases when two conditions are met: 1) when
the risk difference, Pr(Y ≤ 1 | A = 1) − Pr(Y ≤ 2 | A = 0) is larger, 2) the
Pr(Y ≤ 1 | A = 0) is closer to 0.5. Thus the highest power of Fisher’s exact
test is achieved for the uniform control distribution since the risk difference, i.e.
Pr(Y ≤ 1 | A = 1)− Pr(Y ≤ 1 | A = 0), is the largest, and also Pr(Y ≤ 1 | A = 0
is the closest to 0.5. The increase in power when the cumulative logit model is
used, can be attributable to the fact that the test for a treatment effect in the
cumulative logit model is looking at Pr(Y = 1 | A = 1) − Pr(Y =| A = 0) but
also at Pr(Y = 2 | A = 1) − Pr(Y = 2 | A = 0). And with OR1 = 1.65 and
OR2 = 1, the true risk differences are 12% and 11% respectively for the uniform
control distribution, 5% and 5% for the MISTIE II control distribution, and 7% and
7% for the CLEAR II control distribution. Therefore, the cumulative logit model
has a greater chance to detect at least one of these two risk differences being different
from 0 than the fixed dichotomy has on detecting a single non-zero risk difference,
with an exception for the MISTIE II control distribution, where the risk differences
are small at both levels of outcome.
Alternatively, we considered the case where OR1 = 1 and OR2 = 1.65, where the
cumulative logit model has higher power to detect a treatment effect compared to the
fixed dichotomy at Y = 2 for the Uniform and CLEAR II control arm distribution.
Similarly, we note that the Fisher’s exact test when the dichotomy was assigned at
Y = 2 gains more power when the risk difference, Pr(Y ≤ 2 | A = 1) − Pr(Y ≤
2 | A = 0) is larger, and the Pr(Y ≤ 2 | A = 0) is closer to 0.5. For instance,the
highest power is achieved under the MISTIE II control arm distribution because
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the risk difference is the largest with 12% and Pr(Y ≤ 2 | A = 0) is 0.55, being
very close to 0.5. When we set OR1 = 1 and OR2 = 1.65, the cumulative logit
model has higher power than the fixed dichotomy at Y = 2 with an exception for
the MISTIE II control arm distribution, due to similar reasons discussed above;
the cumulative logit model has increased power because it is looking for significant
risk difference at least one value of Y , whereas the fixed dichotomy approach only
looks for significant risk different at a specified cut-off of Y . In this case, the risk
differences between the treatment groups at both Y = 2 and Y = 3 are consistent
within each control arm distribution (10%, 12%, 11% for the Uniform, MISTIE II,
and CLEAR II control distributions, respectively), incorporating risk differences at
both levels provides more power to detect a treatment effect when the cumulative
logit model is used, with an exception for the MISTIE II control arm distribution,
where Pr(Y ≤ 2 | A = 0) is close to 0.5, yields higher power for the fixed dichotomous
approach.
We also considered two scenarios where the fixed dichotomy was favored over
the cumulative logit model. First consider OR1 = 1.65 and OR2 = 1.28. Since the
OR1 > OR2 we expect to see higher power to detect a treatment effect based on the
fixed dichotomy at Y = 1 relative to Y = 2. The fixed dichotomy at Y = 1 approach
yields higher power than the cumulative logit model for the uniform and CLEAR
II control arm distributions. This is attributable to the risk differences between the
treatment groups across all 3 levels of outcomes; the risk differences are 12%, 6%,
and 6% at Y = 1, Y = 2, Y = 3 under the uniform control distribution, and 7%, 1%,
and 6% under the CLEAR II control distribution, where the largest risk difference
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is found at Y = 1, resulting in the higher power when the fixed dichotomy at Y = 1
used to detect a treatment effect, compared to the cumulative logit model. On the
contrary, the risk differences for the MISTIE II control arm distributions are 5%,
1%, and 6% at Y = 1, Y = 2, Y = 3, where the largest difference is found at Y = 3,
thus using the cumulative logit model, which considers the risk difference at all 3
levels, yields higher power than the fixed dichotomy at Y = 1.
Lastly, we considered a case where the fixed dichotomy at Y = 2 has greater
power than the cumulative logit model, OR1 = 1.28 and OR2 = 1.65. First we
see that the power of Fisher’s exact test to detect the treatment effect is higher
when the dichotomy is assigned at Y = 2 than Y = 1 since OR2 > OR1. And
when the cut-off for the fixed dichotomy is assigned at Y = 2, we see that the
Fisher’s exact test yields higher power than the cumulative logit model across all
three control arm distributions for the similar reasons above. With OR1 = 1.28 and
OR2 = 1.65, the risk differences are 6%, 4%, and 10% at Y = 1, Y = 2, Y = 3
under the uniform control arm distribution, 2%, 10%, and 12% under the MISTIE
II control arm distribution, and 3%, 8%, and 11% under the CLEAR II control
arm distribution. We see that the largest risk differences are at Y = 3, which are
mathematically equivalent to the risk differences for Y ≤ 2 when we have 3 outcome
categories. Thus by dichotomizing the outcomes at Y = 2, the Fisher’s exact test
has an advantage in detecting the treatment effect since the largest risk difference is
found at Y ≤ 2.
Based on the four cases we present above, we noted that even with the same odds
ratios, the proportion of treatment patients in each outcome category is different
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based on the pre-specified control arm distribution. In addition, we highlighted
several cases where the cumulative logit model was superior (inferior) to the fixed
dichotomy approach in terms of power.
Table 4.1: Comparison of the Pr(Y ≤ k) for k = 1, 2 and the power to detect a
treatment effect assuming assuming different odds ratios
Control arm
distribution
Pr(Y≤ 1) Pr(Y≤2) Power to detect the treatment effect
A = 0 A = 1 A = 0 A = 1 CLM FD at Y=1 FD at Y=2
OR1 = 1.65 and OR2 = 1
Uniform 0.33 0.45 0.67 0.67 0.86 0.75 0.04
MISTIE II 0.11 0.16 0.55 0.55 0.419 0.421 0.04
CLEAR II 0.14 0.21 0.27 0.27 0.81 0.51 0.04
OR1 = 1 and OR2 = 1.65
Uniform 0.33 0.33 0.67 0.77 0.70 0.04 0.67
MISTIE II 0.11 0.11 0.55 0.67 0.72 0.04 0.74
CLEAR II 0.14 0.14 0.27 0.38 0.83 0.04 0.71
OR1 = 1.65 and OR2 = 1.28
Uniform 0.33 0.45 0.67 0.72 0.68 0.75 0.22
MISTIE II 0.11 0.16 0.55 0.61 0.43 0.42 0.25
CLEAR II 0.14 0.21 0.27 0.33 0.46 0.51 0.22
OR1 = 1.28 and OR2 = 1.65
Uniform 0.33 0.39 0.67 0.77 0.60 0.24 0.67
MISTIE II 0.11 0.13 0.55 0.67 0.68 0.12 0.74
CLEAR II 0.14 0.17 0.27 0.38 0.69 0.14 0.71
4.2.5 When the proportional odds assumption holds
We also considered the special case where the proportional odds assumption holds
(OR1 = OR2) and compared the power to detect a treatment effect using the pro-
portional odds model (a 1 degree of freedom test for OR) with the Fisher’s exact test
for the fixed dichotomy at Y = 1 or Y = 2, also with the cumulative logit model (a 2
degree of freedom test for OR1 and OR2). Figure 4.7 displays the estimated powers
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Figure 4.7: Power comparison when the proportional odds assumption holds
centered at OR = 1, based on different statistical methods across the control arm
distributions. Given our sample size of n = 500 patients, for each of the assumed
control group distributions, the proportional odds model outperforms the fixed di-
chotomous approach in terms of power to detect a treatment effect. Comparing the
two fixed dichotomy approaches, in general, the power is higher when the dichotomy
is assigned at Y = 2 relative to Y = 1. However, for the uniform control distribu-
tion, the fixed dichotomy at Y = 1 yields greater power than the fixed dichotomy at
Y = 2 when the OR > 1. Also, the cumulative logit model yields lower power than
the proportional odds model due to the extra 1 degree of freedom in the cumulative
logit model.
We created an example table to understand the results more numerically. Ta-
ble 4.2 presents cumulative proportions in each treatment group across the three con-
trol arm distributions as well as the power estimates when we assume OR = 1.65. By
incorporating the treatment effect happening at both levels in the outcomes, but not
paying penalty for an extra degree of freedom as in the cumulative logit model, the
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proportional odds model (POM) achieves the highest power to detect the treatment
effect when the proportional odds assumption is true.
Table 4.2: Comparison of the Pr(Y ≤ k) for k = 1, 2 and the power to detect a




Pr(Y≤1) Pr(Y≤2) Power to detect the treatment effect
A = 0 A = 1 A = 0 A = 1 POM FD atY=1
FD at
Y=2 CLM
Uniform 0.33 0.45 0.67 0.77 0.86 0.75 0.67 0.78
MISTIE II 0.11 0.16 0.55 0.67 0.83 0.42 0.74 0.75




We sought to identify characteristics of the distributions of the control and treat-
ment group that provide higher power to detect a treatment effect when applying a
fixed dichotomy to an ordered categorical outcome. The simulation study considered
an ordered categorical outcome with three levels and three different control group
distributions.
When choosing between the ordinal approach vs. fixed dichotomous approach,
it is important to understand where the treatment effect is among the levels of
outcomes. When it is reasonable to assume proportional odds, using the proportional
odds model with the ordinal outcome yields higher power to detect a treatment effect
compared to a fixed dichotomous approach or the cumulative logit model.
More careful consideration is required when the proportional odds assumption
does not hold. In such cases, we found that the fixed dichotomous approach is
superior than the ordinal approach when the dichotomy of the outcome is assigned
at the level c, where the treatment effect maximizes the risk difference between
Pr(Y ≤ c | A = 1) and Pr(Y ≤ c | A = 0). In addition to the risk difference at the
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level c, the Fisher’s exact test gains power to detect a treatment as Pr(Y ≤ c | A = 0)
being closer to 0.5.
The cumulative logit model yeilds higher power copmared to the proportional
odds model and fixed dichotomy approach when the treatment group comparisons
occurring at each level of the outcome have different directions (i.e. control is favored
at one cut-point but then treatment is favored at the next cut-point).
We have considered an ordinal outcome with three levels; however, in practice,
many ordinal scales used in practice may have more then 3 levels. This work needs to
be extended to the general case. In addition, in practice, the cumulative logit model
is seldom implemented. Instead, the proportional odds model is more frequently
adapted even when the proportional odds assumption is not valid. How to compare
the power to detect a treatment effect when the wrong model is implemented is a
further area of interest.
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